

ITEMS RECOMMENDED BETWEEN ORDINARY MEETINGS (JULY 2020 – SEPTEMBER 2020)

SPONSOR, TYPE OF SUBMISSION	DRUG TYPE AND USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME
<p>OZANIMOD</p> <p>Capsule 230 micrograms Capsule 460 micrograms Capsule 920 micrograms</p> <p>Zeposia®</p> <p>Celgene Pty Ltd</p> <p>New listing (Matters outstanding)</p>	<p>Relapsing-remitting multiple sclerosis (RRMS)</p>	<p>To request an Authority Required listing for the treatment of patients with RRMS.</p>	<p>The PBAC recommended, out of session, the Authority Required (STREAMLINED) listing of ozanimod for the treatment of relapsing remitting multiple sclerosis (RRMS) on a cost-minimisation basis with fingolimod, following confirmation ozanimod was now TGA registered. The PBAC noted ozanimod was not TGA registered when previously considered at its March 2020 meeting.</p> <p>In making this recommendation, the PBAC recalled its March 2020 consideration and reaffirmed its view that based on the available evidence, ozanimod was of superior comparative efficacy to interferon beta-1a and likely to be of non-inferior comparative safety and efficacy to fingolimod.</p>